The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management.

@article{Atri2019TheAD,
  title={The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management.},
  author={Alireza Atri},
  journal={The Medical clinics of North America},
  year={2019},
  volume={103 2},
  pages={
          263-293
        }
}
  • A. Atri
  • Published 1 March 2019
  • Medicine
  • The Medical clinics of North America
Alzheimer's disease (AD) care requires timely diagnosis and multidisciplinary management. Evaluation involves structured patient and caregiver history and symptom-function reviews, examination, and testing (laboratory and neuroimaging) to delineate impairment level, determine the cognitive-behavioral syndrome, and diagnose cause. Clinical biomarkers are available to aid high confidence in etiologic diagnosis. Management uses psychoeducation, shared goal setting, and patient-caregiver dyad… 
Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis
TLDR
Emerging optimism for improved outcomes in AD stems from a focus on preventive interventions in midlife and timely, biomarker‐confirmed diagnosis at early signs of cognitive deficits, which is particularly important for optimizing patient care and enabling the appropriate use of anticipated DMTs.
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
TLDR
Data on the currently explored biomarkers in terms of AD pathology-specific and non-specific biomarkers are reviewed and the recent developments in the diagnostic and theragnostic domains are highlighted.
New approaches to symptomatic treatments for Alzheimer’s disease
TLDR
Advances in developing new agents for cognitive and behavioral symptoms of AD combined with enhanced trial methods promise to address the unmet needs of patients with AD for improved cognition and amelioration of neuropsychiatric symptoms.
Assessing the Progression of Alzheimer’s Disease in Real-World Settings in Three European Countries
TLDR
A mixed model developed for cognitive, functional, and neuropsychiatric scores, obtained from study patients at baseline and during follow-up period, showed progressive deterioration of AD patients over time.
The cognitive dysfunction related to Alzheimer disease or cerebral small vessel disease
TLDR
The cognitive dysfunctions of AD are difference to that of CSVD patients, and diabetes is the risk factor both for AD and CSVD, future studies are needed to further identify the prevention and treatment of AD andCSVD.
Urinary Incontinence and Alzheimer’s Disease: Insights From Patients and Preclinical Models
TLDR
There is preliminary data suggesting these models have similar voiding behavior to Alzheimer’s disease patients but much more research is needed to understand the link between UI and Alzheimer's disease and discover better treatment options for managing both simultaneously.
Oral Health and Care for Elderly People with Alzheimer’s Disease
TLDR
The purpose of this paper is to provide an overview of oral health and the importance of oral care for elderly people with Alzheimer’s disease, as the techniques used to provide this support vary depending on the elderly people concerned.
Vitamins in Alzheimer’s Disease—Review of the Latest Reports
TLDR
A properly balanced diet, as well as the use of appropriate supplementation, can contribute to improving the clinical condition of patients with AD.
Improved Alzheimer’s Disease Detection by MRI Using Multimodal Machine Learning Algorithms
TLDR
A framework based on supervised learning classifiers in the dementia subject categorization as either AD or non-AD based on longitudinal brain MRI features is proposed and results mentioned that the gradient boosting algorithm outperforms other models with 97.58% of accuracy.
Body Fluid Biomarkers for Alzheimer’s Disease—An Up-To-Date Overview
TLDR
The aim of this paper is to provide an overview of both conventional and novel biomarkers for AD found within body fluids, including CSF, blood, saliva, urine, tears, and olfactory fluids.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 138 REFERENCES
Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice.
  • A. Atri
  • Psychology, Medicine
    Handbook of clinical neurology
  • 2016
TLDR
This chapter reviews clinical applications and imaging findings useful in medical practice relating to neurodegenerative cognitive/dementing disorders and suggests combination use of imaging methods will likely improve diagnostic accuracy.
Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
TLDR
The pharmacological rationale for its use, and the current clinical evidence for its efficacy and long-term effectiveness in the management of cognitive and behavioral symptoms in moderate to severe stages of Alzheimer’s disease are examined.
Effective pharmacologic management of Alzheimer's disease.
TLDR
Evidence-based guidelines outlining pharmacotherapeutic strategies can be systematically implemented to optimize outcomes for patients in different stages of Alzheimer's disease to help physicians in the effective pharmacologic management of this challenging population.
Alzheimer's disease
TLDR
An overview of recent evidence regarding the epidemiology, pathogenesis, diagnosis, and treatment of Alzheimer's disease is provided, and potential ways to reduce the risk of developing the disease are discussed.
The Evaluation of Rapidly Progressive Dementia
TLDR
A standardized stepwise approach is outlined for patients presenting with RPD and neurologists should adopt a standardized approach to the rapidly presenting disease processes that may mimic CJD in their clinical and radiologic features.
Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer’s Disease
TLDR
In this population of moderate and severe AD patients, treatment with memantine was associated with reducing worsening of clinical symptoms in AD during the 6-month study period.
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
TLDR
The new guidelines recognize the pre‐clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, and establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP‐43 inclusions.
Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors.
TLDR
This follow-up offers a unique opportunity to compare the 1-year evolution of the disease in clinical practice before and after the marketing of CEIs and allows us to demonstrate a clinically significant improvement in patient outcome over time.
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
TLDR
These new criteria are centred on a clinical core of early and significant episodic memory impairment and stipulate that there must also be at least one or more abnormal biomarkers among structural MRI, molecular neuroimaging with PET, and cerebrospinal fluid analysis of amyloid beta or tau proteins.
Long-term progression of Alzheimer’s disease in patients under antidementia drugs
TLDR
The effects of standard of care for AD patients on the prognosis of the disease in a real‐life study over a 4‐year period is examined.
...
1
2
3
4
5
...